Ob polypeptides, modified forms and compositions thereto
First Claim
1. An immunogenic fragment of an OB polypeptide, said fragment selected from the group consisting of:
- (a) SEQ ID NO;
18;
(b) SEQ ID NO;
19;
(c) SEQ ID NO;
20; and
(d) SEQ ID NO;
21.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates generally to the control of body weight of animals including mammals and humans, and more particularly to materials identified herein as modulators of weight, and of the diagnostic and therapeutic uses to such modulators. In its broadest aspect, the present invention relates to the elucidation and discovery of nucleotide sequences, and proteins putatively expressed by such nucleotides or degenerate variations thereof, that demonstrate the ability to participate in the control of mammalian body weight. The nucleotide sequences in object represent the genes corresponding to the murine and human ob gene, that have been postulated to play a critical role in the regulation of body weight and adiposity. Preliminary data, presented herein, suggests that the polypeptide product of the gene in question functions as a hormone. The present invention further provides nucleic acid molecules for use as molecular probes, or as primers for polymerase chain reaction (PCR) amplification, i.e., synthetic or natural oligonucleotides. In further aspects, the present invention provides a cloning vector, which comprises the nucleic acids of the invention; and a bacterial, insect, or a mammalian expression vector, which comprises the nucleic acid molecules of the invention, operatively associated with an expression control sequence. Accordingly, the invention further relates to a bacterial or a mammalian cell transfected or transformed with an appropriate expression vector, and correspondingly, to the use of the above mentioned constructs in the preparation of the modulators of the invention. Also provided are antibodies to the ob polypeptide. Moreover, a method for modulating body weight of a mammal is provided.
81 Citations
45 Claims
-
1. An immunogenic fragment of an OB polypeptide, said fragment selected from the group consisting of:
-
(a) SEQ ID NO;
18;
(b) SEQ ID NO;
19;
(c) SEQ ID NO;
20; and
(d) SEQ ID NO;
21.
-
-
2. An OB polypeptide analog, capable of modulating body weight, comprising amino acids 22-167 of SEQ ID NOS:
- 2 or 4, wherein one or more amino acids selected from the group consisting of amino acids 53, 56, 71, 85, 89, 92, 95, 98, 110, 118, 121, 122, 126, 127, 128, 129, 132, 139, 157, 159, 163, and 166 is substituted with another amino acid.
- View Dependent Claims (9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)
-
3. An OB polypeptide analog, capable of modulating body weight, comprising amino acids 22-167 of SEQ ID NO:
- 4 wherein the analog is selected from the group consisting of polypeptides wherein;
(a) the serine residue at position 53 is substituted with glycine, alanine, valine, cysteine, methionine, or threonine;
(b) the serine residue at position 98 is substituted with glycine, alanine, saline, cysteine, methionine, or threonine; and
(c) the arginine residue at position number 92 is substituted with asparagine, lysine, histidine, glutamine, glutamic acid, aspartic acid, serine, threonine, methionine, or cysteine.
- 4 wherein the analog is selected from the group consisting of polypeptides wherein;
-
4. An OB polypeptide capable of modulating body weight, comprising amino acids 22-167 of SEQ ID NOS:
- 2 or 4 or amino acids 22-166 of SEQ ID NO;
5 or 6, wherein said polypeptide has an N-terminal amino acid sequence selected from the group consisting of;(a) SEQ ID NO;
38;
(b) SEQ ID NO;
98;
(c) SEQ ID NO;
26;
(d) SEQ ID NO;
27;
(e) SEQ ID NO;
28;
(f) SEQ ID NO;
99; and
(g) glycine-serine-proline.
- 2 or 4 or amino acids 22-166 of SEQ ID NO;
-
5. An OB polypeptide analog, capable of modulating body weight, comprising amino acids 22-167 of SEQ ID NOS:
- 2 or 4, wherein one or more amino acids selected from the group consisting of amino acids 53, 56, 71, 85, 89, 92, 95, 98, 110, 118, 121, 122, 126, 127, 128, 129, 132, 139, 157, 159, 163, and 166 is substituted with another amino acid and wherein said analog has an N-terminal amino acid sequence selected from the group consisting of;
(a) SEQ ID NO;
38;
(b) SEQ ID NO;
98;
(c) SEQ ID NO;
26;
(d) SEQ ID NO;
27;
(e) SEQ ID NO;
28;
(f) SEQ ID NO;
99; and
(g) glycine-serine-proline.
- 2 or 4, wherein one or more amino acids selected from the group consisting of amino acids 53, 56, 71, 85, 89, 92, 95, 98, 110, 118, 121, 122, 126, 127, 128, 129, 132, 139, 157, 159, 163, and 166 is substituted with another amino acid and wherein said analog has an N-terminal amino acid sequence selected from the group consisting of;
-
6. An OB polypeptide analog, capable of modulating body weight, comprising amino acids 22-166 of SEQ ID NOS:
- 5 or 6, wherein one or more amino acids selected from the group consisting of amino acids 52, 55, 70, 84, 88, 91, 94, 97, 109, 117, 120, 121, 125, 126, 127, 128, 131, 138, 156, 158, 162, and 165 is substituted with another amino acid.
-
7. An OB polypeptide analog, capable of modulating body weight, comprising amino acids 22-166 of SEQ ID NO:
- 6 wherein the analog is selected from the group consisting of polypeptides wherein;
(a) the serine residue at position 52 is substituted with glycine, alanine, valine, cysteine, methionine, or threonine;
(b) the serine residue at position 97 is substituted with glycine, alanine, valine, cysteine, methionine, or threonine; and
(c) the arginine residue at position number 91 is substituted with asparagine, lysine, histidine, glutamine, glutamic acid, aspartic acid, serine, threonine, methionine, or cysteine.
- 6 wherein the analog is selected from the group consisting of polypeptides wherein;
-
8. An OB polypeptide analog, capable of modulating body weight, comprising an amino acids 22-166 of SEQ ID NOS:
- 5 or 6, wherein one or more amino acids selected from the group consisting of amino acids 52, 55, 70, 84, 88, 91, 94, 97, 109, 117, 120, 121, 125, 126, 127, 128, 131, 138, 156, 158, 162, and 165 is substituted with another amino acid and wherein said analog has an N-terminal amino acid sequence selected from the group consisting of;
(a) SEQ ID NO;
38;
(b) SEQ ID NO;
98;
(c) SEQ ID NO;
26;
(d) SEQ ID NO;
27;
(e) SEQ ID NO;
28;
(f) SEQ ID NO;
99; and
(g) glycine-serine-proline.
- 5 or 6, wherein one or more amino acids selected from the group consisting of amino acids 52, 55, 70, 84, 88, 91, 94, 97, 109, 117, 120, 121, 125, 126, 127, 128, 131, 138, 156, 158, 162, and 165 is substituted with another amino acid and wherein said analog has an N-terminal amino acid sequence selected from the group consisting of;
Specification